AR037111A1 - Formulacion solida para utilizar como medicamento a base de un derivado de piperazinurea procedimiento para su preparacion y su uso - Google Patents

Formulacion solida para utilizar como medicamento a base de un derivado de piperazinurea procedimiento para su preparacion y su uso

Info

Publication number
AR037111A1
AR037111A1 ARP020103929A ARP020103929A AR037111A1 AR 037111 A1 AR037111 A1 AR 037111A1 AR P020103929 A ARP020103929 A AR P020103929A AR P020103929 A ARP020103929 A AR P020103929A AR 037111 A1 AR037111 A1 AR 037111A1
Authority
AR
Argentina
Prior art keywords
solid formulation
piperazinurea
preparation
medication based
derivative procedure
Prior art date
Application number
ARP020103929A
Other languages
English (en)
Spanish (es)
Inventor
Tack Johannes
Heiko Kranz
Christoph Voelkel
Ralph Lipp
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR037111A1 publication Critical patent/AR037111A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP020103929A 2001-10-18 2002-10-18 Formulacion solida para utilizar como medicamento a base de un derivado de piperazinurea procedimiento para su preparacion y su uso AR037111A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
AR037111A1 true AR037111A1 (es) 2004-10-20

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103929A AR037111A1 (es) 2001-10-18 2002-10-18 Formulacion solida para utilizar como medicamento a base de un derivado de piperazinurea procedimiento para su preparacion y su uso

Country Status (23)

Country Link
EP (1) EP1435917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506365A (cg-RX-API-DMAC7.html)
KR (1) KR20040047920A (cg-RX-API-DMAC7.html)
CN (1) CN1571660A (cg-RX-API-DMAC7.html)
AR (1) AR037111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002333896B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213340A (cg-RX-API-DMAC7.html)
CA (1) CA2463951A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580740A2 (cg-RX-API-DMAC7.html)
DE (1) DE10152351B4 (cg-RX-API-DMAC7.html)
EC (1) ECSP045108A (cg-RX-API-DMAC7.html)
HR (1) HRP20040435A2 (cg-RX-API-DMAC7.html)
IL (1) IL161166A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003522A (cg-RX-API-DMAC7.html)
NO (1) NO20042022L (cg-RX-API-DMAC7.html)
NZ (1) NZ532287A (cg-RX-API-DMAC7.html)
PE (1) PE20030472A1 (cg-RX-API-DMAC7.html)
PL (1) PL367987A1 (cg-RX-API-DMAC7.html)
RS (1) RS32204A (cg-RX-API-DMAC7.html)
RU (1) RU2311172C2 (cg-RX-API-DMAC7.html)
UY (1) UY27500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035037A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403781B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Also Published As

Publication number Publication date
DE10152351B4 (de) 2005-09-22
CN1571660A (zh) 2005-01-26
MXPA04003522A (es) 2004-07-23
AU2002333896B2 (en) 2007-07-26
NO20042022L (no) 2004-05-14
PE20030472A1 (es) 2003-06-16
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06
RU2004115328A (ru) 2005-06-10
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
HRP20040435A2 (en) 2005-06-30
RU2311172C2 (ru) 2007-11-27
BR0213340A (pt) 2004-10-05
JP2005506365A (ja) 2005-03-03
DE10152351A1 (de) 2003-05-08
WO2003035037A1 (de) 2003-05-01
KR20040047920A (ko) 2004-06-05
UY27500A1 (es) 2003-06-30
NZ532287A (en) 2007-04-27
RS32204A (sr) 2006-10-27
CO5580740A2 (es) 2005-11-30
IL161166A0 (en) 2004-08-31
ECSP045108A (es) 2004-06-28
ZA200403781B (en) 2004-11-29

Similar Documents

Publication Publication Date Title
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
UY28510A1 (es) Compuestos quimicos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
PA8551001A1 (es) Nuevos compuestos
UY27446A1 (es) Nuevos compuestos
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR039868A1 (es) Inhibidores selectivos de la enzima kalikreina plasmatica
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP034895A (es) Composiciones farmacéuticas de adsorbatos de fármaco amorfo
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR047928A1 (es) Derivados de tetrahidropiridoindol
AR048963A1 (es) Formulaciones de interferon de hidrogel de poloxamero
AR037248A1 (es) Compuestos de n-benzoil-5-tiofen-2-sulfonamida y n-benzoil-2-tiazol-5-sulfonamida, formulacion farmaceutica que los comprende y su uso para fabricacion de un medicamento
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR040226A1 (es) Productos parenterales antifungicos
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
SV2008002527A (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure